Fatal insomnia
Fatal Insomnia is a terrifyingly rare neurodegenerative disease that gradually robs its victims of the ability to sleep, transforming a fundamental human need into a relentless torment. This genetic nightmare progresses through stages of worsening sleeplessness, panic, and hallucinations, ultimately leading to dementia and death. It offers a stark reminder of the brain's intricate vulnerabilities and the devastating impact of even the smallest genetic error. Fatal Insomnia is a prion disease, caused by misfolded proteins that relentlessly damage the brain, primarily the thalamus, which regulates sleep. The disease exists in both a hereditary form (FFI), linked to a specific mutation on the PRNP gene, and a rarer sporadic form (sFI), sharing similar pathological mechanisms. Despite profound research efforts, there is currently no cure, and treatments are limited to palliative care, emphasizing the urgent need for therapeutic breakthroughs.
AI Summary
Fatal Insomnia is a terrifyingly rare neurodegenerative disease that gradually robs its victims of the ability to sleep, transforming a fundamental human need into a relentless torment. This genetic nightmare progresses through stages of worsening sleeplessness, panic, and hallucinations, ultimately leading to dementia and death. It offers a stark reminder of the brain's intricate vulnerabilities and the devastating impact of even the smallest genetic error.
- Fatal Insomnia is a prion disease, caused by misfolded proteins that relentlessly damage the brain, primarily the thalamus, which regulates sleep.
- The disease exists in both a hereditary form (FFI), linked to a specific mutation on the PRNP gene, and a rarer sporadic form (sFI), sharing similar pathological mechanisms.
- Despite profound research efforts, there is currently no cure, and treatments are limited to palliative care, emphasizing the urgent need for therapeutic breakthroughs.
The Unending Night: What is Fatal Insomnia?
Imagine a condition where sleep becomes a forgotten luxury, a distant memory you can no longer grasp. That is the grim reality of Fatal Insomnia, a devastating neurodegenerative disorder. It begins subtly, as simple trouble falling asleep, but inexorably tightens its grip, leaving its victims in a waking nightmare.
This relentless disease primarily manifests in two forms: Fatal Familial Insomnia, or FFI, which is hereditary and linked to a specific genetic mutation, and a much rarer sporadic form, known as sFI. Both share the tragic hallmark symptom: a progressive, irreversible inability to sleep.
The Descent into Sleeplessness: Symptoms
The journey through Fatal Insomnia is typically divided into four stages, each more harrowing than the last. It often begins with worsening insomnia, leading to profound panic attacks, intense paranoia, and inexplicable phobias. This initial stage can last for about four months, slowly eroding the victim's peace of mind.
As the disease advances, around the second stage, vivid hallucinations begin to plague the individual, often accompanied by more frequent and intense panic attacks. These terrifying experiences can persist for approximately five months, blurring the lines between reality and nightmare.
The third stage marks a complete inability to sleep at all — a state known as agrypnia excitata. This total sleeplessness is often paired with rapid and severe weight loss, a testament to the body's profound distress. This agonizing period typically lasts for about three months.
Finally, the disease culminates in the fourth stage: severe dementia. During this period, which can span around six months, the individual becomes largely unresponsive, often mute, as their cognitive functions severely decline. Death inevitably follows this final, heartbreaking stage.
Beyond the core sleep disturbances, patients experience a range of other distressing symptoms. These include profuse sweating, pinpoint pupils (miosis), sudden onset of menopause or impotence, and unexplained neck stiffness. There can also be elevated blood pressure and heart rate, indicating widespread autonomic system dysfunction.
As the brain struggles with the lack of sleep, individuals often become trapped in a state of pre-sleep limbo, or hypnagogia. This is the fuzzy boundary between wakefulness and sleep that healthy people experience briefly. But for those with Fatal Insomnia, it's a prolonged, fragmented existence, often marked by repetitive limb movements, as if stuck in an endless dream.
The Prion Culprit: A Misfolded Protein
Fatal Insomnia belongs to a terrifying class of diseases known as prion diseases. These conditions are caused by the accumulation of misfolded prion proteins in the brain. Unlike bacteria or viruses, prions are not living organisms; they are simply normal proteins that have adopted an abnormal, infectious shape, compelling other healthy proteins to misfold too.
These abnormal prions gradually clump together, forming aggregates that damage brain cells. Prion diseases are notoriously stealthy, often accumulating silently for many years without causing any symptoms — a long incubation period. But once symptoms appear, the disease progresses rapidly and mercilessly.
The Genetic Root: Fatal Familial Insomnia (FFI)
The familial form of the disease, FFI, is a rare inherited prion disorder caused by a specific mutation in the PRNP gene. This gene is located on chromosome 20 and provides the instructions for making the prion protein, PrPC. A tiny, yet devastating, error in this gene initiates the disease.
Specifically, FFI results from a missense mutation at codon 178 of the PRNP gene. This changes the amino acid aspartic acid (GAC) to asparagine (AAC) at that crucial position. But there's another piece to the puzzle: this change must be accompanied by the presence of a methionine codon at position 129 of the mutant allele.
This is an autosomal dominant disease, meaning that a person needs to inherit only one copy of the mutated PRNP gene from a parent to develop the condition. Each child of an affected parent has a 50% chance of inheriting the mutation. The age of onset for FFI varies wildly, from 13 to 60 years old, with an average of 50.
The Rarer Cousin: Sporadic Fatal Insomnia (sFI)
While FFI is genetic, a small number of cases are sporadic, meaning they arise spontaneously without a family history or known genetic mutation. As of 2022, only 37 cases of sFI had been diagnosed worldwide, making it exceptionally rare compared to its genetic counterpart.
Intriguingly, sFI is also linked to the PRNP gene, but without the D178N mutation seen in FFI. Instead, sFI patients invariably show methionine homozygosity at codon 129. This subtle genetic difference leads to similar pathological outcomes, highlighting the complex ways prion proteins can go awry.
The Brain Under Attack: Pathophysiology
The core of Fatal Insomnia's pathology lies in the degeneration of the thalamus, a deep brain structure critical for regulating sleep, consciousness, and relaying sensory information. Prion accumulation here drastically reduces glucose metabolism, effectively 'starving' the region of energy.
This hypometabolism also extends to the cingulate cortex, another vital brain area involved in emotion, memory, and executive function. The extent of this metabolic decline can vary between individuals, potentially influenced by genetic variations at codon 129, further complicating the disease's presentation.
Diagnosis and Prognosis
Diagnosing Fatal Insomnia involves a combination of observing clinical symptoms, conducting sleep studies, and utilizing advanced imaging techniques like PET scans. Genetic testing is crucial for FFI cases, especially when there's a family history. However, as with all prion diseases, a definitive diagnosis can only be confirmed by a brain autopsy post-mortem.
Newer diagnostic tools are emerging, such as the real-time quaking-induced conversion (RT-QuIC) assay, which can detect tiny amounts of misfolded prion proteins in cerebrospinal fluid. Additionally, 18F-FDG-PET scans can reveal severe hypometabolism in the thalamus even in early stages, offering hope for earlier detection.
Like all known prion diseases, Fatal Insomnia is invariably fatal. The life expectancy after symptom onset ranges from a mere six months to six years, with an average survival time of about 18 months. This rapid, relentless progression underscores the severity of the disease and the urgent need for effective therapies.
A History of Discovery and Despair
The story of Fatal Insomnia begins in late 1983, when Italian neurologist Dr. Ignazio Roiter encountered a patient named Silvano at the University of Bologna. Silvano, battling this mysterious and horrifying illness, made the courageous decision to be recorded and to donate his brain for research, hoping his sacrifice could help future generations.
Three years later, in 1986, Professor Elio Lugaresi and his colleagues, building on Silvano's case, officially named and meticulously described the clinical and neuropathological features of Fatal Familial Insomnia. This landmark publication laid the foundation for understanding this enigmatic disease, though its prion nature was not fully understood at the time.
By 1998, researchers had identified 40 families worldwide carrying the FFI gene, spanning continents from Europe to America, Australia, and Japan. This global distribution highlights the pervasive, albeit rare, presence of this genetic vulnerability across human populations.
Heartbreaking individual stories further illuminate the disease's impact. In 2001, an unnamed 52-year-old American man, facing FFI, heroically attempted to extend his life with various strategies, including vitamin therapy, meditation, stimulants, and even sensory deprivation. He managed to survive for nearly a year beyond the average, writing a book and traveling, yet ultimately succumbed to the illness's unforgiving progression.
Another case in 2011 involved a 57-year-old Egyptian man living in the Netherlands. His symptoms began with double vision and memory loss, escalating to disorientation, paranoia, and confusion. Despite periods of falling asleep during the day, his nights were filled with vivid dreams and involuntary muscle jerks, painting a clear picture of his disordered sleep-wake cycle. He passed away just seven months after symptom onset, with an autopsy revealing the characteristic thalamic atrophy.
Treatment and Hope for the Future
Currently, there is no known disease-modifying treatment or cure for Fatal Insomnia. Care is primarily palliative, focusing on managing symptoms and providing comfort to patients and their families. While some medications, like clonazepam for spasms or eszopiclone for insomnia, may offer temporary relief, they do not halt the disease's progression.
Research is ongoing, with some tentative successes in slowing disease progression in animal models using compounds like pentosan polysulfate and doxycycline. The ultimate goal is to find a way to prevent or reverse the misfolding of prion proteins, offering true hope for future patients.
A powerful example of this research drive comes from the Prion Alliance, founded by Eric Minikel and Sonia Vallabh after Sonia's mother was diagnosed with FFI. They conduct dedicated research at the Broad Institute, driven by the hypothesis that lowering the levels of normal prion protein (PrP) could prevent the onset of the disease, embodying a profound personal commitment to overcoming this medical mystery.
Article
Fatal insomnia
Fatal insomnia is a neurodegenerative prion disease that results in trouble sleeping as its hallmark symptom. The majority of cases are familial (fatal familial insomnia [FFI]), stemming from a mutation in the PRNP gene, with the remainder of cases occurring sporadically (sporadic fatal insomnia [sFI]). The problems with sleeping typically start out gradually and worsen over time. Eventually, the patient will succumb to total insomnia (agrypnia excitata), most often leading to other symptoms such as speech problems, coordination problems, and dementia. It results in death within a few months to a few years, and there is no known disease-modifying treatment for now.
Signs and symptoms
Fatal insomnia
• Characterized by worsening insomnia, resulting in panic attacks, paranoia, and phobias. This stage lasts for about four months. • Hallucinations and panic attacks become noticeable, continuing for about five months. • Complete inability to sleep followed by rapid loss of weight. This lasts for about three months. • Dementia, during which the person becomes unresponsive or mute over the course of six months, is the final stage of the disease, followed by death.
Other symptoms include profuse sweating, miosis (pinpoint pupils), sudden entrance into menopause or impotence, neck stiffness, and elevation of blood pressure and heart rate. The sporadic form of the disease often presents with double vision. Prolonged constipation is common as well. As the disease progresses, the person becomes stuck in a state of pre-sleep limbo, or hypnagogia, which is the state just before sleep in healthy individuals. During these stages, people commonly and repeatedly move their limbs as if they were dreaming.
The age of onset is variable, ranging from 13 to 60 years, with an average of 50. The disease can be detected prior to onset by genetic testing. Death usually occurs between 6–36 months from onset. The presentation of the disease varies considerably from person to person, even among people within the same family; in the sporadic form, for example, sleep problems are not commonly reported, and early symptoms are ataxia, cognitive impairment, and double vision.
Cause
Fatal insomnia
Idiogram of chromosome 20 showing gene PRP location
Fatal familial insomnia is a rare hereditary prion disease that is associated with a mutation in PRNP. The gene, which provides instructions for making the prion protein PrPC, is located on the short arm of chromosome 20 at position p13. Individuals with FFI or familial Creutzfeldt–Jakob disease (fCJD) both carry a mutation at codon 178 of the prion protein gene. FFI is also invariably linked to the presence of the methionine codon at position 129 of the mutant allele, whereas fCJD is linked to the presence of the valine codon at that position. The disease occurs when there is a change of amino acid at position 178 in which asparagine is found instead of the normal aspartic acid. This has to be accompanied with a methionine at position 129.
FFI is an autosomal dominant disease caused by a missense GAC-to-AAC mutation at codon 178 of the PRNP prion protein gene located on chromosome 20, along with the presence of the methionine polymorphism at position 129 of the mutant allele. Pathologically, FFI is characterized predominantly by thalamic degeneration—especially in the medio-dorsal and anteroventral nuclei. Phenotypic variability is a perplexing feature of FFI.
Pathophysiology
Fatal insomnia
In itself the presence of prions causes reduced glucose to be used by the thalamus and a mild hypo-metabolism of the cingulate cortex. The extent of this symptom varies between two variations of the disease: those presenting methionine homozygotes at codon 129 and methionine/valine heterozygotes, with some evidence that hypo-metabolism is more severe in the latter. Given the relationship between the involvement of the thalamus in regulating sleep and alertness, a causal relationship can be drawn and is often mentioned as the cause of insomnia.
Diagnosis
Fatal insomnia
The real-time quaking-induced conversion (RT-QuIC), a highly sensitive assay that detects minute amounts of PrPSc in the cerebrospinal fluid, has been reported to have a sensitivity of 50% in FFI and sFI.
A test that measures the cerebral metabolic rate of glucose is performed by positron emission tomography (PET), using the radiotracer [18F]-FDG-PET which is a glucose analogue, Fatal Familial Insomnia has demonstrated severe hypometabolism of the thalamus bilaterally in FFI and sFI, also in the earliest stages of the disease. The hypometabolism would show a build up of glucose due to the thalamus using less glucose then normal, this would also align with symptoms of insomnia like sleep regulation, autonomic and cognitive functions and motor information. This hypometabolism then spreads as the disease progresses/worsens, eventually impacting most cortical regions, like cortex, basal ganglia, brainstem and others.
Differential diagnosis
Other diseases involving the mammalian prion protein are known.
Treatments
Fatal insomnia
Treatment involves palliative care. There is conflicting evidence over the use of sleeping pills, including barbiturates, as a treatment for the disease.
Clonazepam may be prescribed to treat muscle spasms, and eszopiclone or zolpidem may be prescribed to help treat insomnia. However, these drugs do not work in the long term.
Prognosis
Fatal insomnia
Timeline of a fatal familial insomnia (FFI) patient
Like all prion diseases, FFI is invariably fatal. Life expectancy ranges from seven months to six years, with an average of 18 months.
Epidemiology and history
Fatal insomnia
Hypnogram comparing the sleep pattern of a healthy control with five FFI patients, who display decreased sleep efficiency and disrupted sleep cycles (W: wake; R: REM; N1-3: NREM sleep stages.)
Fatal insomnia was first described by Elio Lugaresi et al. in 1986.
In 1998, 40 families were known to carry the gene for FFI globally: eight German, five Italian, four American, two French, two Australian, two British, one Japanese and one Austrian. In the Basque Country of Spain, 16 family cases of the 178N mutation were seen between 1993 and 2005 related to two families with a common ancestor in the 18th century. In 2011, another family was added to the list when researchers found the first man in the Netherlands to be diagnosed with FFI. Whilst he had lived in the Netherlands for 19 years, he was of Egyptian descent. Other prion diseases are similar to FFI and may be related but are missing the D178N gene mutation.
As of 20 September 2022, 37 cases of sporadic fatal insomnia have been diagnosed. Unlike in FFI, those with sFI do not have the D178N mutation in the PRNP gene; they all have a different mutation in the same gene causing methionine homozygosity at codon 129. Nonetheless, the methionine presence in lieu of the valine (Val129) is what causes the sporadic form of disease. The targeting of this mutation has been suggested as a strategy for treatment, or possibly as a cure for the disease.
Silvano, 1983, Bologna, Italy
In late 1983, Italian neurologist/sleep expert Dr. Ignazio Roiter received a patient at the University of Bologna hospital's sleep institute. The man, known only as Silvano, decided in a rare moment of consciousness to be recorded for future studies and to donate his brain for research in hopes of finding a cure for future victims.
In 1986, Lugaresi and colleagues first named and described in detail the clinical and histopathological features of fatal familial insomnia. This report was primarily based on the aforementioned Silvano. Dr. Roiter referred the case to Prof. Elio Lugaresi, a well-known sleep expert, who, along with his colleagues, carried out advanced sleep analyses. As Silvano's condition quickly deteriorated, Lugaresi arranged for a postmortem neuropathological examination of the brain to be carried out by Dr. Gambetti, Lugaresi's former trainee. The collaboration of these two groups led to the 1986 publication. At the time, a prion disease was not suspected due to a lack of prion-related histopathology and frozen brain tissue for advanced analysis. However, due to the devotion of Dr. Roiter and Silvano's family, more cases were obtained, resulting in the classification of FFI as a familial prion disease tied to the 178Asn genetic mutation.
Unnamed American patient, 2001
In an article published in 2006, Schenkein and Montagna wrote of a 52-year-old American man who was able to exceed the average survival time by nearly one year with various strategies that included vitamin therapy and meditation, different stimulants and hypnotics and even complete sensory deprivation in an attempt to induce sleep at night and increase alertness during the day. He managed to write a book and drive hundreds of miles in this time, but nonetheless, over the course of his trials, the man succumbed to the classic four-stage progression of the illness.
Egyptian man, 2011, Netherlands
In 2011, the first reported case in the Netherlands was of a 57-year-old man of Egyptian descent. The man came in with symptoms of double vision and progressive memory loss, and his family also noted he had recently become disoriented, paranoid and confused. Whilst he tended to fall asleep at random during daily activities, he experienced vivid dreams and random muscular jerks during normal slow-wave sleep. After four months of these symptoms, he began to have convulsions in his hands, trunk and lower limbs while awake. The person died at age 58, seven months after the onset of symptoms. An autopsy revealed mild atrophy of the frontal cortex and moderate atrophy of the thalamus. The latter is one of the most common signs of FFI.
Research
Fatal insomnia
Still with unclear benefit in humans, a number of treatments have had tentative success in slowing disease progression in animal models, including pentosan polysulfate, mepacrine, and amphotericin B. As of 2016, a study investigating doxycycline is being carried out.
In 2009, a mouse model was made for FFI. These mice expressed a humanized version of the PrP protein that also contains the D178N FFI mutation. These mice appear to have progressively fewer and shorter periods of uninterrupted sleep, damage in the thalamus, and early deaths, similar to humans with FFI.
The Prion Alliance was established by husband and wife duo Eric Minikel and Sonia Vallabh after Vallabh's mother was diagnosed with the fatal disease. They conduct research at the Broad Institute to develop therapeutics for human prion diseases. Their hypothesis is that lowering PrP-levels may prevent the onset of FFI. Other research interests involve identifying biomarkers to track the progression of prion disease in living people.